

PITUS 18 – 20 Working Groups Update September & October 2020

Working Group 1 – Evaluation and Promotion Chair – Catherine Pitman

Meeting 21 – 13 October 2020

- * Further updates to [Draft SPIA Exemplar Reports](#) were approved; accompanying HL7 V2, CDA & FHIR messages generated and compliance checking undertaken by Angus Millar at ADHA
- * Manual SPIA compliance audits completed for 23 SPIA report elements across Urea Electrolytes and Creatinine reports (August 2019 IEQA Survey) and Hepatitis B reports (September 2020 IEQA Survey). Very good compliance (>92%) noted for: Headings used and differentiated from test names; use of Patient identifiers; Patient sex; Date format; inclusion of report interpretation
- * WG1 Questionnaire (19 August 2020) received 7 responses with common response themes 1) need SPIA to be mandated to drive adoption 2) need to lobby relevant groups to drive uptake of SPIA Standards

Working Group 2 – Terminology Development Chair – Lawrie Bott

TD Chemical Pathology – Meeting 13, 22 September 2020

- * 34 LOINC terms reviewed; 25 LOINC terms approved; 3 LOINC codes rejected; 6 LOINC terms further review

TD Chemical Pathology Subject Matter Expert (Blood Gases & POCT) – Meeting 11, 08 September 2020

- * Discussions targeted draft recommendations for implementation of RCPA SPIA Blood Gas reference sets (requesting and reporting terms) discussed, with first step being a workshop with major LIS/CIS software vendors, presenting current issues including barriers to adoptions, draft RCPA Exemplar Reports, draft summary of proposed recommendations, identification of goals e.g. national set of standardised terminologies

TD Chemical Pathology Subject Matter Expert (Blood Gases & POCT) – Meeting 12, 06 October 2020

- * RCPA Exemplar Report layout refined further; additional updates to report subheaders, analytes typically reported for blood gases, etc.
- * Draft combined arterial & venous Exemplar Report to be created for review at Meeting 13

TD Chemical Pathology Subject Matter Expert (Protein EPP) – no meetings September or October 2020

TD Haematology – No further meetings, all terms reviewed

TD Immunopathology – No further meetings, all terms reviewed

TD Microbiology, Serology & Molecular Biology – Meeting 13, 13 October 2020

- * 67 LOINC terms reviewed; 58 LOINC terms approved; 9 LOINC codes rejected; 8 LOINC codes for further review; 13 Syphilis LOINC terms for review; 9 LOINC terms to be requested from Regenstrief
- * 15 SNOMED codes for review
- * No further meetings planned; remaining terminology to be reviewed out of session by 30 November 2020

Working Group 3 – Systems Design and Compliance Chair – Vanessa Cameron

No meetings September & October 2020

Working Group 4 – SPRC Infostructure and Conformance Chair – David Ellis

Meeting 21 – 21 September 2020 – cancelled quorum not met

Meeting 22 – 20 October 2020

- * Colorectal Cancer, Polypectomy & Endometrial Cancer protocols transformed into FHIR resources; Cervical and Ovary, Fallopian tube Cancer protocol transformations underway with publication expected in November
- * RCPAQAP testing of automated Conformance checking software for Colorectal SPRC Protocol revealed many conformance issues, mainly due to poor quality data in HL7 messages provided for testing
- * WG4 members met with New Zealand Cancer Control Agency to discuss [Action Plan 2019-2029](#) and how RCPA can assist with structured reporting of cancers to registries

Working Group 5 – Report Standardisation Chair – Graham Jones

Meeting 27 – 01 September 2020

- * Straw man proposals reviewed for report headers and test groupings: Lipid Profile and Biochemistry – General
- * Best Practice Guidelines draft outline reviewed

Meeting 28 – 29 September 2020

- * Straw man proposals for report headers and test groupings completed for: Lipid profile and Biochemistry – General, Full blood count, Coagulation and Protein studies,

Meeting 29 – 13 October 2020

- * Straw man proposals for report headers and test groupings completed for: MCS urine, Chromosome studies, Haemochromatosis gene screening, Immunoglobulin E, Chlamydia trachomatis nucleic acid, Histology and Hepatitis B Serology
- * Straw man proposals for report headers and test groupings to be circulated widely for comment as part of decision-making process for final recommendations